Cholesterol-lowering injections are no longer all alike. Antibody PCSK9 inhibitors are given every two or four weeks. A newer class, small interfering RNA (siRNA), is given at much longer intervals. For hospital pharmacies, cardiology units and procurement teams in India, a six-monthly schedule changes how stock, recall and cold chain are planned. This article reports the published trial data and the supply points. It does not recommend any treatment.
How siRNA LDL-lowering therapy works
PCSK9 is a protein that reduces the number of LDL receptors on liver cells. Inclisiran is an siRNA that reduces the liver’s production of PCSK9, so more LDL receptors remain available to clear LDL cholesterol from the blood. It is a different mechanism from antibody PCSK9 inhibitors such as evolocumab, which bind PCSK9 already circulating in the blood. Our earlier post on the PCSK9 guideline and the available agents in India compares them.
What ORION-10 and ORION-11 reported
Two phase 3 trials, ORION-10 (1,561 patients) and ORION-11 (1,617 patients), compared inclisiran with placebo. Both gave inclisiran as a subcutaneous injection every six months.
| ORION-10 | ORION-11 | |
|---|---|---|
| Patients | 1,561 | 1,617 |
| Baseline mean LDL-C | 2.71 mmol/L | 2.73 mmol/L |
| LDL-C change vs placebo at day 510 | −52.3% | −49.9% |
| Time-averaged LDL-C reduction vs placebo | 53.8% | 49.2% |
These trials used LDL-C change as the primary end point. They were not designed to show differences in cardiovascular events, so they report lipid lowering and not outcome benefit.
Dosing schedule and administration
The product listing for Sybrava (inclisiran) 284 mg/1.5 mL states a subcutaneous dose of 284 mg on day 1, again at month 3, then every six months, supplied as a single-dose prefilled syringe. Storage is stated as 2°C to 8°C, no freezing, protected from light. For comparison, the Repatha listing describes an antibody PCSK9 inhibitor given more often. Always check current prescribing information.
Supply and logistics planning for a six-monthly injection
- Recall and scheduling: with only two doses a year after the first three months, a documented recall system matters. A missed visit is a planning gap for the hospital and prescriber to manage.
- Cold chain: record receipt and storage temperatures against the label, and protect syringes from light.
- Stock timing: because use is intermittent, order against scheduled visits to avoid holding stock close to expiry.
- Genuine supply: source from a distributor that can document origin and paperwork. See our guide on verifying genuine imported medicines.
- Access routes: medicines not routinely stocked in India may be available through the Named Patient Program, and manufacturer schemes are explained on our Patient Assistance Program page.
Medicines are supplied only against a valid prescription from a registered medical practitioner.
Working with a medicine distributor in Delhi
A.K. Pharma is a Medicine Distributor in Delhi supplying imported and specialty medicines to hospitals, clinics and doctors across India. To check availability or plan stock for scheduled visits, contact the team at 011 4172 6999 or on WhatsApp at +91 9810034827.
Frequently asked questions
What is an siRNA LDL cholesterol therapy?
It is a small interfering RNA medicine that reduces production of the PCSK9 protein in the liver, which lowers LDL cholesterol. Inclisiran is the siRNA agent in this class.
How was inclisiran dosed in the ORION trials?
In the ORION-10 and ORION-11 trials, inclisiran was given by subcutaneous injection every six months.
How much LDL-C lowering did the ORION trials report?
At day 510, LDL-C was 52.3% lower than placebo in ORION-10 and 49.9% lower in ORION-11. Time-averaged reductions were 53.8% and 49.2%.
Did the ORION-10 and ORION-11 trials measure cardiovascular outcomes?
No. They were LDL-C trials with LDL-C change as the primary end point. They were not designed to show differences in cardiovascular events.
How does an siRNA differ from an antibody PCSK9 inhibitor?
Antibody PCSK9 inhibitors such as evolocumab bind PCSK9 in the blood and are given more frequently. The siRNA approach reduces PCSK9 synthesis in the liver and is given at longer intervals.
What is the dosing schedule on the product listing?
The listing states 284 mg on day 1, again at month 3, then every 6 months, given as a subcutaneous injection. Always follow the current prescribing information.
How should the prefilled syringe be stored?
The listing states storage at 2°C to 8°C, no freezing, protected from light. Hospitals should confirm against the current package insert.
Why do administration logistics matter for a six-monthly injection?
A two-dose-a-year schedule depends on a documented recall system and reliable stock at each visit. Missed visits are a planning matter for the hospital and the prescriber.
Is this article medical advice?
No. A.K. Pharma is a distributor, not a healthcare provider. Treatment decisions rest solely with the treating physician.
Sources
ORION-10 and ORION-11 figures: NHS Medicines Resources summary of the NEJM publication. Product details: A.K. Pharma listing.
Disclaimer: A.K. Pharma is a medicine distributor, not a healthcare provider. This article reports published trial and guideline information and is not medical advice. Treatment decisions rest solely with the treating physician.
